Ixaka’s MCT therapies draw on an extensive research of the fundamental science of cell therapies. They have been developed by the Andalusian Health Authority through the Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RADITTA) which form a network of clinical and biomedical research facilities.
RADITTA is a global leader in advanced therapies and has sponsored over 20 ongoing and completed clinical trials in the areas of cardiology, peripheral vascular disease, neurology, hematology, gastroenterology, ophthalmology and infectious diseases and operates 10 GMP facilities for advanced therapies in Andalusia.
Our license partners Servicio Andaluz de Salud (SAS), the Andalusian Regional Ministry of Health, and Fundación Progreso y Salud (FPS), which is part of the Andalusian Regional Ministry of Health, are part of this network.
Ixaka is also a partner in the Midland Wales Advanced Therapy Treatment Centre (MW-ATTC). The ATTC Network Programme is a world-first, UK system of Advanced Therapy Treatment Centres (ATTC) operating within the NHS framework and coordinated by the Cell and Gene Therapy Catapult to address the unique and complex challenges of bringing pioneering advanced therapy medicinal products (ATMPs) to patients.